JSPR

Jasper Therapeutics Inc

0.7202

Aug 25 • 3:59 PM ET -0.0022 (-0.30%)

0.7021

Aftermarket • 6:32 PM ET -0.0181 (-2.51%)

Healthcare Biotechnology USA Nano NASD

Peers: ALLR BCTX CLRB LGVN MRKR NXTC PLUR PTN TPST VTGN

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	23.96M
Enterprise Value	16.50M
Income	-31.77M
Sales	0.00M
Book/sh	0.05
Cash/sh	0.23
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	22
IPO	Jan 10, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	14.31
P/C	3.10
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.47
Current Ratio	1.47
Debt/Eq	0.19
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.58
EPS next Y	-0.53
EPS next Q	-0.10
EPS this Y	85.64%
EPS next Y	6.86%
EPS next 5Y	46.38%
EPS past 3/5Y	27.39% 48.97%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.74%
Sales Y/Y TTM	-
EPS Q/Q	94.48%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	62.66% -

Insider Own	11.95%
Insider Trans	0.00%
Inst Own	27.64%
Inst Trans	-11.00%
ROA	-109.05%
ROE	-255.05%
ROIC	-2248.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.64%
SMA50	13.52%
SMA200	-35.97%
Trades

Shs Outstand	33.27M
Shs Float	29.30M
Short Float	18.29%
Short Ratio	3.51
Short Interest	5.36M
52W High	3.00 -75.99%
52W Low	0.32 128.56%
Volatility	9.73% 14.39%
ATR (14)	0.10
RSI (14)	50.24
Beta	3.04
Rel Volume	0.18
Avg Volume	1.53M
Volume	271,830

Perf Week	-3.97%
Perf Month	3.73%
Perf Quarter	-21.08%
Perf Half Y	-47.81%
Perf YTD	-60.64%
Perf Year	-75.67%
Perf 3Y	-94.50%
Perf 5Y	-99.28%
Perf 10Y	-
Recom	1.50
Target Price	7.12
Prev Close	0.72
Price	0.72
Change %	-0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-26	Initiated	Piper Sandler	Overweight	$2
May-15-26	Downgrade	TD Cowen	Buy → Hold
Mar-23-26	Resumed	UBS	Neutral	$1.50
Jan-13-26	Initiated	Rodman & Renshaw	Buy	$17
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$5
Jul-08-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$4
Jul-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Jul-07-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Initiated	UBS	Buy	$38
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$63
Sep-09-24	Initiated	JMP Securities	Mkt Outperform	$70
Jul-08-24	Initiated	BTIG Research	Buy	$90
Jun-27-24	Initiated	Stifel	Buy	$86
May-06-24	Initiated	H.C. Wainwright	Buy	$65
Apr-03-24	Initiated	Evercore ISI	Outperform	$65
Mar-28-24	Initiated	RBC Capital Mkts	Outperform	$70
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight	$7
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-08-21	Initiated	Credit Suisse	Outperform	$15

Show Previous Ratings

Aug-17-26 08:30AM	Jasper Therapeutics beats Q2 expectations but shares fall after results (InvestorsHub) +6.59%
Aug-14-26 11:00AM	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -8.46%
Jul-17-26 07:54AM	Jasper gets a lifeline in merger with immune drugmaker Kira (BioPharma Dive) +14.34%
Jul-16-26 05:15PM	Jasper Therapeutics Announces Merger with Kira Pharmaceuticals (GlobeNewswire) +11.85%
Jun-01-26 08:00AM	Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (GlobeNewswire) -35.56%
04:05PM	Loading…
May-14-26 04:05PM	Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -11.36%
Mar-30-26 04:30PM	Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -14.29%
Feb-24-26 04:30PM	Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Jan-09-26 07:15AM	Jasper Therapeutics reports updated data from briquilimab studies (TipRanks) -9.04%
Jan-08-26 07:00AM	Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria (GlobeNewswire) -19.02%
Jan-07-26 04:30PM	Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth (GlobeNewswire) +7.89%
Dec-02-25 07:00AM	Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation (GlobeNewswire) -8.14%
Dec-01-25 04:30PM	Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation (GlobeNewswire) -6.52%
Nov-11-25 02:15AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Nov-10-25 08:00AM	Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
03:37AM	Loading…
Nov-07-25 03:37AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Nov-04-25 08:00AM	Jasper Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -13.81%
Oct-20-25 03:21AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Oct-07-25 08:04AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Sep-25-25 04:46PM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire) +6.01%
Sep-22-25 05:58PM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights JSPR (Business Wire) -5.51%
Sep-19-25 12:07AM	Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants (GlobeNewswire)
Sep-18-25 04:08PM	Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants (GlobeNewswire) +11.16%
Aug-27-25 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 04:05PM	Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-09-25 08:00AM	Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway (GlobeNewswire) +21.85%
Jul-07-25 07:30AM	Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria (GlobeNewswire) -55.10%
Jun-14-25 10:00AM	Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire)
Jun-03-25 08:00AM	Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress (GlobeNewswire) +8.26%
May-21-25 11:23AM	Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential (Insider Monkey)
04:30PM	Loading…
May-14-25 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-12-25 04:05PM	Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-25 04:21PM	Jasper Therapeutics files $300M mixed securities shelf (SeekingAlpha)
Mar-01-25 12:45PM	Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-28-25 08:00AM	Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Feb-27-25 08:00AM	Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-25 04:30PM	Jasper Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-10-25 08:00AM	Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-04-25 04:30PM	Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire) +8.23%
Jan-08-25 07:00AM	Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire) -60.53%
Jan-06-25 08:00AM	Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025 (GlobeNewswire) +8.30%
Dec-02-24 04:30PM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma (GlobeNewswire) +5.09%
Nov-13-24 04:30PM	Jasper Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-08-24 11:28AM	Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise (GuruFocus.com) +8.11%
Nov-07-24 07:30AM	Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-24 08:00AM	Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-23-24 08:00AM	Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria (GlobeNewswire)
Oct-14-24 07:00AM	Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +10.46%
Sep-10-24 07:30AM	Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma (GlobeNewswire) +5.13%
Sep-04-24 04:30PM	Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 07:00AM	Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.40%
Jun-19-24 08:00AM	Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors (GlobeNewswire)
Jun-17-24 04:30PM	Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit (GlobeNewswire)
Jun-14-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress (GlobeNewswire)
May-30-24 06:05PM	Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 (GlobeNewswire) +7.72%
May-29-24 04:30PM	Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-13-24 08:00AM	Jasper Therapeutics Announces Briquilimab Development Program in Asthma (GlobeNewswire)
May-07-24 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire) -6.94%
12:00PM	Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-02-24 04:30PM	Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
Mar-22-24 08:50AM	Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-21-24 04:30PM	Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) +8.01%
Mar-19-24 08:00AM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +5.55%
Mar-15-24 08:00AM	New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
Mar-14-24 12:00PM	Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know (Zacks) -9.11%
Mar-06-24 12:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +8.21%
08:50AM	Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going (Zacks)
Mar-04-24 07:30AM	Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-26-24 04:30PM	Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-23-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-19-24 08:50AM	Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength (Zacks)
Feb-07-24 08:00AM	Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference (GlobeNewswire) +18.00%
Feb-06-24 08:59AM	Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock (GlobeNewswire) +14.52%
Feb-05-24 08:00AM	Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire) +7.65%
Feb-02-24 08:00AM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-24 12:14PM	Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why (Zacks)
Jan-05-24 08:30AM	Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones (GlobeNewswire)
Jan-02-24 08:00AM	Jasper Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -13.74%
Dec-18-23 04:30PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.11%
Dec-10-23 11:00AM	Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 (GlobeNewswire)
Nov-30-23 08:00AM	Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-09-23 09:48AM	Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -8.08%
08:00AM	Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors (GlobeNewswire)
Oct-09-23 08:30AM	Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023 (GlobeNewswire) +16.25%
08:00AM	Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Sep-25-23 08:00AM	Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer (GlobeNewswire) -8.97%
Sep-21-23 08:00AM	Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium (GlobeNewswire)
Sep-15-23 08:00AM	Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference (GlobeNewswire) +10.96%
Aug-11-23 04:05PM	Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-04-23 04:51PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 08:00AM	Jasper Therapeutics Strengthens Management Team with Key Appointments (GlobeNewswire)
Jun-22-23 08:00AM	Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome (GlobeNewswire)
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
Jun-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer (GlobeNewswire) +6.17%
May-12-23 04:05PM	Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +5.37%

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Executive ChairmanMr. Thomas G. Wiggans

PresidentMr. Jeetinder Singh Mahal M.B.A.

Ph.D.Dr. Judith Anne Shizuru M.D.

CFO & Corporate SecretaryMr. Herbert C. Cross CPA

Chief Operating OfficerMr. Matthew E. Ros

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WIGGANS THOMAS G	Director	Sep 22 '25	Buy	2.43	41,000	99,630	41,000	Sep 24 04:01 PM
Lucas Svetlana	Director	Sep 22 '25	Buy	2.43	20,000	48,600	20,000	Sep 24 04:01 PM
MARTELL RON	President and CEO	Sep 22 '25	Buy	2.43	41,000	99,630	74,118	Sep 24 04:01 PM
Shizuru Judith Anne	Director	Sep 22 '25	Buy	2.43	41,000	99,630	156,901	Sep 24 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JSPR

Jasper Therapeutics Inc

Upgrade your Finviz experience